DB:8EV

Stock Analysis Report

Executive Summary

Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Evgen Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8EV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.2%

8EV

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

-76.9%

8EV

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: 8EV underperformed the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: 8EV underperformed the German Market which returned 6.1% over the past year.


Shareholder returns

8EVIndustryMarket
7 Day16.2%-4.1%-5.7%
30 Day-33.8%-8.2%-5.7%
90 Day-47.8%-2.0%-3.6%
1 Year-76.9%-76.9%4.0%3.7%9.3%6.1%
3 Yearn/a38.2%36.7%8.9%-0.7%
5 Yearn/a9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Evgen Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Evgen Pharma undervalued compared to its fair value and its price relative to the market?

1.2x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 8EV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 8EV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 8EV is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 8EV is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8EV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8EV is good value based on its PB Ratio (1.2x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Evgen Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-8.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8EV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8EV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8EV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8EV's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 8EV's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 8EV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Evgen Pharma performed over the past 5 years?

1.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8EV is currently unprofitable.

Growing Profit Margin: 8EV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8EV is unprofitable, but has reduced losses over the past 5 years at a rate of 1.1% per year.

Accelerating Growth: Unable to compare 8EV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8EV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 8EV has a negative Return on Equity (-46.69%), as it is currently unprofitable.


Next Steps

Financial Health

How is Evgen Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: 8EV's short term assets (£5.5M) exceed its short term liabilities (£353.0K).

Long Term Liabilities: 8EV has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 8EV is debt free.

Reducing Debt: 8EV currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: 8EV has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 8EV's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 8EV has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 8EV has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of -14.6% each year.


Next Steps

Dividend

What is Evgen Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8EV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 8EV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8EV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8EV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8EV's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Steve Franklin 0

UK£228,300

Compensation

Dr. Stephen J. Franklin, also known as Steve, serves Chief Executive Officer of Evgen Pharma Plc. He has been an Executive Director at Evgen Pharma plc since October 2, 2014. He has over 20 years’ commerci ...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD297.01K) is about average for companies of similar size in the German market ($USD415.76K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Stephen Franklin
CEO & Executive Director0yrsUK£228.30k1.07% £80.5k
Richard Moulson
CFO & Executive Director3.1yrsUK£93.68k0.031% £2.4k
Liz Jenkins
Regulatory Consultant0yrsno datano data
Thomas Morris
Consultant & Medical Advisor of Oncology2.9yrsno datano data
Albena Dinkova-Kostova
Independent Scientific Advisor2.1yrsno datano data
Giovanni Mann
Independent Scientific Advisor2.1yrsno datano data

2.5yrs

Average Tenure

Experienced Management: 8EV's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stephen Franklin
CEO & Executive Director0yrsUK£228.30k1.07% £80.5k
Richard Moulson
CFO & Executive Director3.1yrsUK£93.68k0.031% £2.4k
Susan Foden
Senior Independent Director0yrsUK£26.50kno data
Barry Clare
Non-Executive Chairman3.2yrsUK£35.00k0.32% £24.5k
Alan Barge
Non-Executive Director4.3yrsUK£24.30kno data
Susan Clement-Davies
Non-Executive Director1.3yrsUK£9.38kno data

3.2yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 8EV's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.8%.


Top Shareholders

Company Information

Evgen Pharma plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Evgen Pharma plc
  • Ticker: 8EV
  • Exchange: DB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£6.301m
  • Listing Market Cap: UK£7.535m
  • Shares outstanding: 132.65m
  • Website: https://www.evgen.com

Number of Employees


Location

  • Evgen Pharma plc
  • The Colony
  • Altrincham Road
  • Wilmslow
  • Cheshire
  • SK9 4LY
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EVGAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPOct 2015
8EVDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2015

Biography

Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company’s lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 23:31
End of Day Share Price2020/02/25 00:00
Earnings2019/09/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.